1. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update onacute coronary syndromes: the pathologists’ view. Eur Heart J.2013;34(10):719-728.
2. Balta S, Kurtoglu E, Kucuk U, Demirkol S, Ozturk C. Neutrophil-lymphocyte ratio as an important assessment tool. Expert RevCardiovasc Ther. 2014;12(5):537-538.
3. Budzianowski J, Pieszko K, Burchardt P, Rzezniczak J, HiczkiewiczJ. The role of hematological indices in patients with acute coronarysyndrome. Dis Markers. 2017;2017:3041565.
4. Ji Y, Wang H. Prognostic prediction of systemic immune-inflammationindex for patients with gynecological and breast cancers:a meta-analysis. World J Surg Oncol. 2020;18(1):1-11.
5. Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis.Cancer Cell Int. 2020;20(1):1-8.
6. Haybar H, Pezeshki SMS, Saki N. Evaluation of complete blood countparameters in cardiovascular diseases: an early indicator of prognosis?Exp Mol Pathol. 2019;110:104267.
7. Al-Kindi SG, Refaat M, Jayyousi A, Asaad N, Al Suwaidi J, AbiKhalil C. Red cell distribution width is associated with all-cause andcardiovascular mortality in patients with diabetes. Biomed Res Int.2017;2017:5843702.
8. Ozcan F, Turak O, Durak A, et al. Red cell distribution width andinflammation in patients with non-dipper hypertension. Blood Press.2013;22(2):80-85.
9. Abrahan LL 4th, Ramos JDA, Cunanan EL, Tiongson MDA, PunzalanFER. Red cell distribution width and mortality in patients withacute coronary syndrome:a meta-analysis on prognosis. Cardiol Res.2018;9(3):144-152.
10. Borné Y, Smith JG, Melander O, Hedblad B, Engström G. Red celldistribution width and risk for first hospitalization due to heart failure:a population-based cohort study. Eur J Heart Fail. 2011;13(12):1355-1361.
11. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM.Association between white blood cell count, epicardial blood flow,myocardial perfusion, and clinical outcomes in the setting of acutemyocardial infarction:a thrombolysis in myocardial infarction 10substudy. Circulation. 2000;102 (19):2329-2334.
12. Chia S, Nagurney JT, Brown DF, et al. Association of leukocyte andneutrophil counts with infarct size, left ventricular function andoutcomes after percutaneous coronary intervention for ST-elevationmyocardial infarction. Am J Cardiol. 2009;103(3):333-337.
13. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increasesatherosclerosis in LDL receptor-null mice. Arterioscler Thromb VascBiol. 2002;22(11):1892-1898.
14. Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the bloodlymphocyte count in predicting recurrent instability and death in patientswith unstable angina pectoris. Am J Cardiol. 2000;86(4):449-451.
15. Kelesoglu S, Yilmaz Y, Elcık D, Kalay N. Systemic immune inflammationindex: a novel predictor for coronary collateral circulation. Perfusion.2022;37(6):605-612.
16. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) andcardiovascular diseases:an update. Expert Rev Cardiovasc Ther. 2016;14(5):573-577.
17. Kelesoglu S, Yilmaz Y, Ozkan E, et al. New onset atrial fibrilation andrisk faktors in COVID-19. J Electrocardiol. 2021;65:76-81.
18. Yilmaz Y, Kelesoglu S, Elcik D, Ozmen R, Kalay N. Predictive values ofsystemic immune-inflammation index in new-onset atrial fibrillationfollowing coronary artery bypass grafting. Braz J Cardiovasc Surg.2023;38(1):96-103.
19. Uthamalingam S, Patvardhan EA, Subramanian S, et al. Utility of theneutrophil to lymphocyte ratio in predicting long-term outcomes inacute decompensated heart failure. Am J Cardiol. 2011;107(3):433-438.
20. Baysal E, Burak C, Cay S, et al. The neutrophil to lymphocyte ratiois associated with severity of rheumatic mitral valve stenosis. J BloodMed. 2015;6:151-156.
21. King AH, Kim AH, Kwan S, et al. Elevated neutrophil tolymphocyte ratio is associated with worse outcomes after carotidendarterectomy in asymptomatic patients. J Stroke Cerebrovasc Dis.2021;30(12):106120.
22. Belaj K, Pichler M, Hackl G, et al. Association of the derivedneutrophil-lymphocyte ratio with critical limb ischemia. Angiology.2016;67(4):350-354.
23. Gary T, Pichler M, Belaj K, et al. Neutrophil-to-lymphocyte ratio andits association with critical limb ischemia in PAOD patients. PLoS One.2013;8(2):e56745.
24. Luo H, Yuan D, Yang H, et al. Post-treatment neutrophil-lymphocyteratio independently predicts amputation in critical limb ischemiawithout operation. Clinics (Sao Paulo). 2015;70(4):273-277.
25. Taşoğlu İ, Sert D, Colak N, Uzun A, Songur M, Ecevit A. Neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio predict thelimb survival in critical limb ischemia. Clin Appl Thromb Hemost.2014;20(6):645-650.
26. Kullar P, Weerakoddy R, Walsh S. Neutrophil-lymphocyte ratiopredicts graft patency following lower limb revascularisation. ActaChir Belg. 2012;112(5):365-368.
27. Balta S, Celik T, Mikhailidis DP, et al. The relation betweenatherosclerosis and the neutrophil-lymphocyte ratio. Clin ApplThromb Hemost. 2016;22(5):405-411.
28. Kalay N, Dogdu O, Koc F, et al. Hematologic parameters andangiographic progression of coronary atherosclerosis. Angiology.2012;63(3):213-217.
29. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Direct viewing ofatherosclerosis in vivo:plaque invasion by leukocytes is initiated bythe endothelial selectins. FASEB J. 2001;15(7):1149-1157.
30. Fernandez-Ruiz I. Neutrophil-driven SMC death destabilizesatherosclerotic plaques. Nat Rev Cardiol. 2019;16(8):455.
31. Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009;9(6):418e28.
32. Hyun S, Kwon S, Cho S, et al. Can the neutrophil-to-lymphocyte ratioappropriately predict carotid artery stenosis in patients with ıschemicstroke?-a retrospective study. J Stroke Cerebrovasc Dis. 2015;24(11):2646-2451.
33. Abo T, Kawamura T. Immunomodulation by the autonomic nervoussystem:therapeutic approach for cancer, collagen diseases, andinflammatory bowel diseases. Ther Apher. 2002;6(5):348e57.
34. Kadoya M, Koyama H, Kurajoh M, et al. Sleep, cardiac autonomicfunction, and carotid atherosclerosis in patients with cardiovascularrisks: HSCAA study. Atherosclerosis. 2015;238:409e14.
35. Kurtul A, Yarlioglues M, Celik IE, et al. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients whounderwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis. 2015;26(8):706-712.
36. Murat SN, Yarlioglues M, Celik IE, et al. The relationship betweenlymphocyte-to-monocyte ratio and bare-metal stent in-stentrestenosis in patients with stable coronary artery disease. Clin ApplThromb Hemost. 2017;23(3):235-240.
37. Ji H, Li Y, Fan Z, et al. Monocyte/lymphocyte ratio predicts theseverity of coronary artery disease: a syntax score assessment. BMCCardiovasc Disord. 2017;17(1):1-8.
38. Gong S, Gao X, Xu F, et al. Association of lymphocyte to monocyteratio with severity of coronary artery disease. Medicine (Baltimore).2018;97(43):e12813.
39. Si Y, Fan W, Han C, Liu J, Sun L. Atherogenic ındex of plasma,triglyceride-glucose index and monocyte-to-lymphocyte ratiofor predicting subclinical coronary artery disease. Am J Med Sci.2021;362(3):285-290.
40. Ertem AG, Yayla C, Acar B, et al. Relation between lymphocyte tomonocyte ratio and short-term mortality in patients with acutepulmonary embolism. Clin Respir J. 2018;12(2):580-586.
41. Silva N, Bettencourt P, Guimarães JT. The lymphocyte-to-monocyteratio:an added value for death prediction in heart failure. Nutr MetabCardiovasc Dis. 2015;25(11):1033-1040.
42. Lin Y, Peng Y, Chen Y, et al. Association of lymphocyte to monocyteratio and risk of in-hospital mortality in patients with acute type Aaortic dissection. Biomark Med. 2019;13(15):1263-1272.
43. Altinbaş Ö, Demiryürek Ş, Işık M, Tanyeli Ö, Dereli Y, GörmüşN. Predictive value of neutrophil-to-lymphocyte, aspartate-to-alanine aminotransferase, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios in severity and side of carotid artery stenosis: arethose significant? Heart Surg Forum. 2021;24(1):E072-E078.
44. Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34(3):326-334.
45. Sun XP, Li J, Zhu WW, et al. Impact of platelet-to-lymphocyte ratio onclinical outcomes in patients with ST-segment elevation myocardialinfarction. Angiology. 2017;68(4):346-353.
46. Yildiz A, Yuksel M, Oylumlu M, et al. The utility of the platelet-lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost.2015;21(3):223-228.
47. Vakili H, Shirazi M, Charkhkar M, Khaheshi I, Memaryan M,Naderian M. Correlation of platelet to lymphocyte ratio and neutrophilto lymphocyte ratio with thrombolysis in myocardial infarction framecount in ST-segment elevation myocardial infarction. Eur J Clin Invest.2017;47(4):322-327.
48. Pereira-Neves A, Fragão-Marques M, Rocha-Neves J, et al. The impactof neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio incarotid artery disease. Port J Card Thorac Vasc Surg. 2021;28(1):45-51.
49. Delcea C, Buzea CA, Vîjan AE, Badila E, Dan GA. The platelet tolymphocyte ratio in heart failure: a comprehensive review. Rom J InternMed. 2023;61(2):84-97.
50. Mráz M, Cinkajzlová A, Kloucková J, et al. Coronary artery diseaseis associated with an increased amount of T lymphocytes in humanepicardial adipose tissue. Mediators Inflamm. 2019;2019:4075086.
51. Abdolmaleki F, Gheibi Hayat SM, Bianconi V, Johnston TP, SahebkarA. Atherosclerosis and immunity: a perspective. Trends CardiovascMed. 2019;29(6):363-371.
52. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil tolymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106(4):470-476.
53. Shaw DM, Merien F, Braakhuis A, Dulson D. T-cells and their cytokineproduction: the anti-inflammatory and immunosuppressive effects ofstrenuous exercise. Cytokine. 2018;104:136-142.
54. Alie N, Eldib M, Fayad ZA, Mani V. Inflammation, atherosclerosis, andcoronary artery disease: PET/CT for the evaluation of atherosclerosisand inflammation. Clin Med Insights Cardiol. 2014;8(3):13-21.
55. Ketelhuth DFJ, Lutgens E, Bäck M, et al. Immunometabolism andatherosclerosis:perspectives and clinical significance: a position paperfrom the working group on atherosclerosis and vascular biology of theEuropean Society of Cardiology. Cardiovasc Res. 2019;115(9):1385-1392.
56. Núñez J, Sanchis J, Bodí V, et al. Relationship between low lymphocytecount and major cardiac events in patients with acute chest pain,a non-diagnostic electrocardiogram and normal troponin levels.Atherosclerosis. 2009;206(1):251-257.
57. Kelesoglu S, Yilmaz Y, Elcik D, et al. Increased serum systemicimmune-inflammation index is independently associated with severityof carotid artery stenosis. Angiology. 2022;7:33197221144934.
58. Çiçek G, Kundi H, Bozbay M, Yayla C, Uyarel H. The relationshipbetween admission monocyte HDL-C ratio with short-term and long-term mortality among STEMI patients treated with successful primaryPCI. Coron Artery Dis. 2016;27(3):176-184.
59. Kalyoncuoglu M, Biter Hİ, Ozturk S, Belen E, Can MM. Predictiveaccuracy of lymphocyte-to-monocyte ratio and monocyte-to-high-density-lipoprotein-cholesterol ratio in determining the slow flow/no-reflow phenomenon in patients with non-ST-elevated myocardialinfarction. Coron Artery Dis. 2020;31(6):518-526.
60. Kundi H, Kiziltunc E, Cetin M, et al. Association of monocyte/HDL-Cratio with SYNTAX scores in patients with stable coronary arterydisease. Herz. 2016;41(6):523-529.
61. Çelik Aİ, Bezgin T, Karaaslan MB, Coşkun R, Çağdaş M. Therelationship between coronary artery calcium score and monocyte tohigh-density lipoprotein cholesterol ratio in patients with stable anginapectoris. Turk Kardiyol Dern Ars. 2022;50(8):583-589.
62. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E. Monocytes incoronary artery disease and atherosclerosis: where are we now? J AmColl Cardiol. 2013;62(17):1541-1551.
63. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamicsduring atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31(7):1506-1516.
64. Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets andthrombosis in acute ischaemic heart disease. Eur Heart J AcuteCardiovasc Care. 2012;1(1):60-74.
65. Mehu M, Narasimhulu CA, Singla DK. Inflammatory cells inatherosclerosis. Antioxidants (Basel). 2022;11(2):233.
66. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume onadmission predicts impaired reperfusion and long-term mortalityin acute myocardial infarction treated with primary percutaneouscoronary intervention. J Am Coll Cardiol. 2005;46(2):284-290.
67. Estévez-Loureiro R, Salgado-Fernández J, Marzoa-Rivas R, et al.Mean platelet volume predicts patency of the infarct-related arterybefore mechanical reperfusion and short-term mortality in patientswith ST-segment elevation myocardial infarction undergoing primarypercutaneous coronary intervention. Thromb Res. 2009;124(5):536-540.
68. Taglieri N, Saia F, Rapezzi C, et al. Prognostic significance of meanplatelet volume on admission in an unselected cohort of patients withnon ST-segment elevation acute coronary syndrome. Thromb Haemost.2011;106(1):132-140.
69. López-Cuenca AA, Tello-Montoliu A, Roldán V, Pérez-Berbel P, ValdésM, Marín F. Prognostic value of mean platelet volume in patients withnon-ST-elevation acute coronary syndrome. Angiology. 2012;63(4):241-244.
70. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as apredictor of cardiovascular risk: a systematic review and meta-analysis.J Thromb Haemost. 2010;8(1):148-156.
71. Çiçek G, Açıkgöz SK, Yayla Ç, Kundi H, İleri M. White blood cellcount to mean platelet volume ratio: a novel and promising prognosticmarker for ST-segment elevation myocardial infarction. Cardiol J.2016;23(3):225-235.
72. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as amodulator of atherosclerosis. N Engl J Med. 2011;364(18):1746-1760.
73. Gawaz M, Langer H, May AE. Platelets in inflammation andatherogenesis. J Clin Invest. 2005;115(12):3378-3384.
74. Zernecke A, Weber C. Chemokines in atherosclerosis: proceedingsresumed. Arterioscler Thromb Vasc Biol. 2014;34(4):742-750.
75. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS,Stefanadis C. The CD40/CD40 ligand system: linking inflammationwith atherothrombosis. J Am Coll Cardiol. 2009;54(8):669-677.
76. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release ofgelatinase A during platelet activation mediates aggregation. Nature.1997;386(6625):616-619.
77. May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M.Engagement of glycoprotein IIb/IIIa (α(IIb)β3) on platelets upregulatesCD40L and triggers CD40L-dependent matrix degradation byendothelial cells. Circulation. 2002;106(16):2111-2117.